ILF2

Across TCGA pan-cancer cohorts, ILF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ILF2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ILF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ILF2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LSCC, HNSC, and COAD are the cancer types where ILF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.880	0.523	.003	31	view →
HNSC	OS	Median	IV	0.540	0.861	.001	23	view →
COAD	DFS	Median	II,III,IV	1.000	0.884	.025	18	view →
GBM	OS	Tertile	All	0.656	0.277	.003	8	view →
PDAC	OS	Tertile	IV	0.905	0.231	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ILF2–LSCC (DFS)

Open the LSCC breakdown →